Intravenous BCNU and AZQ in patients with recurrent malignant gliomas View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1989-09

AUTHORS

W.K.A. Yung, M.I. Harris, J.M. Bruner, L.G. Feun

ABSTRACT

Twenty-four patients with recurrent malignant glioma were treated with intravenous BCNU (80 mg/m2/day × 3 days) alternating with AZQ (8 mg/m2/day × 5 days) every 6–8 weeks. Twenty patients received two or more courses of chemotherapy, ten anaplastic astrocytomas (AA), eight glioblastomas (GBM), and two malignant oligodendrogliomas (Oligo). All had prior surgery and irradiation; one had prior chemotherapy. Median age was 37.5 years. The median Zubrod performance status (PS) was 1. Three patients (15%) achieved response status, and 7 (35%) had stable disease with median times to tumor progression (MTP) of 56 wks and 35 wks. MTP for patients with progression was 11 weeks. No GBM was responsive to chemotherapy and none of the ten patients with stable or responsive disease were older than fifty years. Dose limiting toxicity was consisted of thrombocytopenia and leukopenia. Young patients with recurrent AA and good PS appear more likely to respond to alternating BCNU/AZQ chemotherapy. The overall response rate (response plus stable) of 50% was comparable to that of BCNU alone and the hematologic toxicity was cumulative. More... »

PAGES

237-240

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00172916

DOI

http://dx.doi.org/10.1007/bf00172916

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1053565275

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/2795118


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aziridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzoquinones", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Brain Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carmustine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glioma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yung", 
        "givenName": "W.K.A.", 
        "id": "sg:person.016341673457.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016341673457.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Harris", 
        "givenName": "M.I.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bruner", 
        "givenName": "J.M.", 
        "id": "sg:person.013375073077.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013375073077.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Feun", 
        "givenName": "L.G.", 
        "id": "sg:person.01024115415.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024115415.42"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00165153", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002279955", 
          "https://doi.org/10.1007/bf00165153"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00165185", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002576749", 
          "https://doi.org/10.1007/bf00165185"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02228889", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013718637", 
          "https://doi.org/10.1007/bf02228889"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1989-09", 
    "datePublishedReg": "1989-09-01", 
    "description": "Twenty-four patients with recurrent malignant glioma were treated with intravenous BCNU (80 mg/m2/day \u00d7 3 days) alternating with AZQ (8 mg/m2/day \u00d7 5 days) every 6\u20138 weeks. Twenty patients received two or more courses of chemotherapy, ten anaplastic astrocytomas (AA), eight glioblastomas (GBM), and two malignant oligodendrogliomas (Oligo). All had prior surgery and irradiation; one had prior chemotherapy. Median age was 37.5 years. The median Zubrod performance status (PS) was 1. Three patients (15%) achieved response status, and 7 (35%) had stable disease with median times to tumor progression (MTP) of 56 wks and 35 wks. MTP for patients with progression was 11 weeks. No GBM was responsive to chemotherapy and none of the ten patients with stable or responsive disease were older than fifty years. Dose limiting toxicity was consisted of thrombocytopenia and leukopenia. Young patients with recurrent AA and good PS appear more likely to respond to alternating BCNU/AZQ chemotherapy. The overall response rate (response plus stable) of 50% was comparable to that of BCNU alone and the hematologic toxicity was cumulative.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf00172916", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094205", 
        "issn": [
          "0167-594X", 
          "1573-7373"
        ], 
        "name": "Journal of Neuro-Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "7"
      }
    ], 
    "keywords": [
      "recurrent malignant glioma", 
      "performance status", 
      "anaplastic astrocytoma", 
      "intravenous BCNU", 
      "malignant gliomas", 
      "median Zubrod performance status", 
      "Zubrod performance status", 
      "good performance status", 
      "recurrent anaplastic astrocytoma", 
      "overall response rate", 
      "malignant oligodendroglioma", 
      "prior chemotherapy", 
      "stable disease", 
      "hematologic toxicity", 
      "prior surgery", 
      "younger patients", 
      "median age", 
      "median time", 
      "responsive disease", 
      "response status", 
      "patients", 
      "response rate", 
      "chemotherapy", 
      "BCNU", 
      "glioblastoma", 
      "gliomas", 
      "more courses", 
      "disease", 
      "progression", 
      "weeks", 
      "wk", 
      "AZQ", 
      "toxicity", 
      "status", 
      "leukopenia", 
      "thrombocytopenia", 
      "surgery", 
      "astrocytomas", 
      "years", 
      "oligodendrogliomas", 
      "dose", 
      "age", 
      "MTP", 
      "course", 
      "rate", 
      "irradiation", 
      "time", 
      "BCNU/AZQ chemotherapy", 
      "AZQ chemotherapy"
    ], 
    "name": "Intravenous BCNU and AZQ in patients with recurrent malignant gliomas", 
    "pagination": "237-240", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1053565275"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00172916"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "2795118"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00172916", 
      "https://app.dimensions.ai/details/publication/pub.1053565275"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:03", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_200.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf00172916"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00172916'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00172916'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00172916'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00172916'


 

This table displays all metadata directly associated to this object as RDF triples.

203 TRIPLES      22 PREDICATES      94 URIs      83 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00172916 schema:about N0f63cbf48f234d58a839b8a081b4bba1
2 N193d82bc72b8457fad401ac69bc06a3d
3 N2d2314309f004c8c80cbf3999b49fe9b
4 N37b734ffac1b43d6b2199761edba1510
5 N62130c0828ed4766b98689caf8b82042
6 N77d05d3827194c0eab545a99cdc8f17a
7 N879666919a6f4806a84c0fda609eb1e1
8 Na2a9f373fc414049b7ff9abbeb92552a
9 Nb0fdccd162ea4a62a29dde387baa6441
10 Nc2608975db5f4da3a2226de81a9ac8fd
11 Nd1d76f2ad0624f9aabed3e28cb4c16e5
12 Ndbef09b5dba946cdaf310e8920f00ea5
13 Nddd828bb6ccb4a36af4170e8dd495d88
14 Ne805d273d96d43a8b8b26606035d2c9f
15 Nf5f7cc2c943e4a8391bbc8cf411bf039
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author N5211a2f81c6342a29471ae79707a209a
19 schema:citation sg:pub.10.1007/bf00165153
20 sg:pub.10.1007/bf00165185
21 sg:pub.10.1007/bf02228889
22 schema:datePublished 1989-09
23 schema:datePublishedReg 1989-09-01
24 schema:description Twenty-four patients with recurrent malignant glioma were treated with intravenous BCNU (80 mg/m2/day × 3 days) alternating with AZQ (8 mg/m2/day × 5 days) every 6–8 weeks. Twenty patients received two or more courses of chemotherapy, ten anaplastic astrocytomas (AA), eight glioblastomas (GBM), and two malignant oligodendrogliomas (Oligo). All had prior surgery and irradiation; one had prior chemotherapy. Median age was 37.5 years. The median Zubrod performance status (PS) was 1. Three patients (15%) achieved response status, and 7 (35%) had stable disease with median times to tumor progression (MTP) of 56 wks and 35 wks. MTP for patients with progression was 11 weeks. No GBM was responsive to chemotherapy and none of the ten patients with stable or responsive disease were older than fifty years. Dose limiting toxicity was consisted of thrombocytopenia and leukopenia. Young patients with recurrent AA and good PS appear more likely to respond to alternating BCNU/AZQ chemotherapy. The overall response rate (response plus stable) of 50% was comparable to that of BCNU alone and the hematologic toxicity was cumulative.
25 schema:genre article
26 schema:inLanguage en
27 schema:isAccessibleForFree false
28 schema:isPartOf Nab616a295a6247f68a53e0e5a718c995
29 Nf4bf8b409c504933aa2801d6454300cb
30 sg:journal.1094205
31 schema:keywords AZQ
32 AZQ chemotherapy
33 BCNU
34 BCNU/AZQ chemotherapy
35 MTP
36 Zubrod performance status
37 age
38 anaplastic astrocytoma
39 astrocytomas
40 chemotherapy
41 course
42 disease
43 dose
44 glioblastoma
45 gliomas
46 good performance status
47 hematologic toxicity
48 intravenous BCNU
49 irradiation
50 leukopenia
51 malignant gliomas
52 malignant oligodendroglioma
53 median Zubrod performance status
54 median age
55 median time
56 more courses
57 oligodendrogliomas
58 overall response rate
59 patients
60 performance status
61 prior chemotherapy
62 prior surgery
63 progression
64 rate
65 recurrent anaplastic astrocytoma
66 recurrent malignant glioma
67 response rate
68 response status
69 responsive disease
70 stable disease
71 status
72 surgery
73 thrombocytopenia
74 time
75 toxicity
76 weeks
77 wk
78 years
79 younger patients
80 schema:name Intravenous BCNU and AZQ in patients with recurrent malignant gliomas
81 schema:pagination 237-240
82 schema:productId N28b7b5453ad34bbe83536ed1fc25e246
83 N832d8630d03b46438fba9b2d50f285b1
84 Nae716470b31440d2867ea94b581d47db
85 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053565275
86 https://doi.org/10.1007/bf00172916
87 schema:sdDatePublished 2022-01-01T18:03
88 schema:sdLicense https://scigraph.springernature.com/explorer/license/
89 schema:sdPublisher Nba67cb7d533e46e6beac1e3aa1014999
90 schema:url https://doi.org/10.1007/bf00172916
91 sgo:license sg:explorer/license/
92 sgo:sdDataset articles
93 rdf:type schema:ScholarlyArticle
94 N01b406d62a1344b68319a9c419ea5024 rdf:first sg:person.013375073077.30
95 rdf:rest N81839b4da32c470abf30fde590922df4
96 N0f63cbf48f234d58a839b8a081b4bba1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Carmustine
98 rdf:type schema:DefinedTerm
99 N193d82bc72b8457fad401ac69bc06a3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Female
101 rdf:type schema:DefinedTerm
102 N28b7b5453ad34bbe83536ed1fc25e246 schema:name dimensions_id
103 schema:value pub.1053565275
104 rdf:type schema:PropertyValue
105 N2d2314309f004c8c80cbf3999b49fe9b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Adult
107 rdf:type schema:DefinedTerm
108 N37b734ffac1b43d6b2199761edba1510 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Glioma
110 rdf:type schema:DefinedTerm
111 N401fa45f21214b9e968e7bf4c65977a3 rdf:first N702a741b119b416fa32bbe3bca23269f
112 rdf:rest N01b406d62a1344b68319a9c419ea5024
113 N5211a2f81c6342a29471ae79707a209a rdf:first sg:person.016341673457.32
114 rdf:rest N401fa45f21214b9e968e7bf4c65977a3
115 N62130c0828ed4766b98689caf8b82042 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Aziridines
117 rdf:type schema:DefinedTerm
118 N702a741b119b416fa32bbe3bca23269f schema:affiliation grid-institutes:grid.240145.6
119 schema:familyName Harris
120 schema:givenName M.I.
121 rdf:type schema:Person
122 N77d05d3827194c0eab545a99cdc8f17a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Aged
124 rdf:type schema:DefinedTerm
125 N81839b4da32c470abf30fde590922df4 rdf:first sg:person.01024115415.42
126 rdf:rest rdf:nil
127 N832d8630d03b46438fba9b2d50f285b1 schema:name pubmed_id
128 schema:value 2795118
129 rdf:type schema:PropertyValue
130 N879666919a6f4806a84c0fda609eb1e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Injections, Intravenous
132 rdf:type schema:DefinedTerm
133 Na2a9f373fc414049b7ff9abbeb92552a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Antineoplastic Combined Chemotherapy Protocols
135 rdf:type schema:DefinedTerm
136 Nab616a295a6247f68a53e0e5a718c995 schema:volumeNumber 7
137 rdf:type schema:PublicationVolume
138 Nae716470b31440d2867ea94b581d47db schema:name doi
139 schema:value 10.1007/bf00172916
140 rdf:type schema:PropertyValue
141 Nb0fdccd162ea4a62a29dde387baa6441 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Humans
143 rdf:type schema:DefinedTerm
144 Nba67cb7d533e46e6beac1e3aa1014999 schema:name Springer Nature - SN SciGraph project
145 rdf:type schema:Organization
146 Nc2608975db5f4da3a2226de81a9ac8fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Middle Aged
148 rdf:type schema:DefinedTerm
149 Nd1d76f2ad0624f9aabed3e28cb4c16e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Brain Neoplasms
151 rdf:type schema:DefinedTerm
152 Ndbef09b5dba946cdaf310e8920f00ea5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Benzoquinones
154 rdf:type schema:DefinedTerm
155 Nddd828bb6ccb4a36af4170e8dd495d88 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Adolescent
157 rdf:type schema:DefinedTerm
158 Ne805d273d96d43a8b8b26606035d2c9f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Neoplasm Recurrence, Local
160 rdf:type schema:DefinedTerm
161 Nf4bf8b409c504933aa2801d6454300cb schema:issueNumber 3
162 rdf:type schema:PublicationIssue
163 Nf5f7cc2c943e4a8391bbc8cf411bf039 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Male
165 rdf:type schema:DefinedTerm
166 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
167 schema:name Medical and Health Sciences
168 rdf:type schema:DefinedTerm
169 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
170 schema:name Oncology and Carcinogenesis
171 rdf:type schema:DefinedTerm
172 sg:journal.1094205 schema:issn 0167-594X
173 1573-7373
174 schema:name Journal of Neuro-Oncology
175 schema:publisher Springer Nature
176 rdf:type schema:Periodical
177 sg:person.01024115415.42 schema:affiliation grid-institutes:grid.240145.6
178 schema:familyName Feun
179 schema:givenName L.G.
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024115415.42
181 rdf:type schema:Person
182 sg:person.013375073077.30 schema:affiliation grid-institutes:grid.240145.6
183 schema:familyName Bruner
184 schema:givenName J.M.
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013375073077.30
186 rdf:type schema:Person
187 sg:person.016341673457.32 schema:affiliation grid-institutes:grid.240145.6
188 schema:familyName Yung
189 schema:givenName W.K.A.
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016341673457.32
191 rdf:type schema:Person
192 sg:pub.10.1007/bf00165153 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002279955
193 https://doi.org/10.1007/bf00165153
194 rdf:type schema:CreativeWork
195 sg:pub.10.1007/bf00165185 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002576749
196 https://doi.org/10.1007/bf00165185
197 rdf:type schema:CreativeWork
198 sg:pub.10.1007/bf02228889 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013718637
199 https://doi.org/10.1007/bf02228889
200 rdf:type schema:CreativeWork
201 grid-institutes:grid.240145.6 schema:alternateName Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., 77030, Houston, TX, USA
202 schema:name Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., 77030, Houston, TX, USA
203 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...